<![CDATA[Wet age-related macular degeneration (AMD) is a major cause of irreversible visual impairment in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment, and current guidelines recommend three consecutive monthly loading-dose injections before maintenance therapy. This study involved evaluating the clinical effectiveness of intravitreal ranibizumab in loading doses for improving visual acuity and anatomical outcomes of wet AMD patients, as a retrospective study on 22 patients with wet AMD who received treatment between 2022 and 2024. All patients had received three monthly loading doses of intravitreal ranibizumab, and their medical records indicated their clinical characteristics. Assessment of best-corrected visual acuity (BCVA) used a Snellen chart, whereas measurement of central retinal thickness (CRT) and total macular volume (TMV) used optical coherence tomography. Data analysis used the Chi-square and Mann-Whitney U tests. Following the loading-dose regimen, CRT decreased by a mean of 52 μm (p = 0.038) and TMV by 1.8 μm (p = 0.047). In 59% of patients, their visual acuity improved, and younger individuals had significantly greater improvement (p = 0.029). Earlier disease onset had a significant association with greater reductions in CRT and TMV (p = 0.026). These findings indicated that both anatomical and functional outcomes in patients with wet AMD improved effectively following the loading-dose regimen of intravitreal ranibizumab, with reductions in retinal thickness and macular volume as well as improvements in visual acuity. Younger age and earlier treatment initiation become important prognostic factors in association with better treatment responses]]>
Copyrights © 2026
